check_circleStudy Completed

Neoplasms

Open label Phase I dose escalation study with BAY1143572 in patients with advanced cancer

Trial purpose

The purpose of this study Part A is to determine the safety, tolerability and the pharmacokinetics of BAY1143572 in subjects with advanced malignancies, which are either refractory to or ineligible for treatment with standard agents.
The purpose of this study Part B is:
Determine the safety, tolerability, pharmacokinetics (PK) and maximum tolerated dose (MTDG-CSF) of BAY1143572 with concurrent administration of the granulocyte colony-stimulating factors (G-CSF) in an intermittent and continuous dosing schedule in subjects with advanced malignancies.

Key Participants Requirements

Sex

Both

Age

21 - N/A

Trial summary

Enrollment Goal
80
Trial Dates
September 2013 - September 2016
Phase
Phase 1
Could I Receive a placebo
No
Products
Atuveciclib (BAY1143572)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Seoul, 110-744, Korea, Republic Of
Completed
Singapore, 119228, Singapore
Completed
Singapore, 169610, Singapore
Completed
Seoul, 120-752, Korea, Republic Of
Completed
New York, 10032, United States
Terminated
Boston, 02215, United States
Terminated
Taipei, 10002, Taiwan
Completed
Seoul, 05505, Korea, Republic Of
Completed
Hackensack, 07601, United States
Terminated
Charleston, 29425, United States
Completed
Ann Arbor, 48109, United States
Completed
Fayetteville, 72703, United States
Terminated
Boston, 02215, United States

Primary Outcome

  • Number of participants with adverse events as a measure of safety and tolerability
    date_rangeTime Frame:
    Up to 2 years
    enhanced_encryption
    Safety Issue:
    Yes
  • Maximum tolerated dose (MTD) of BAY1143572
    In Part A: Maximum tolerated dose (MTD) of BAY1143572 In Part B; Maximum tolerated dose ( MTD) with G-CSF of BAY114357 The MTD is defined as the highest dose that can be given such that not more than 20% of subjects experience a dose limiting toxicity (DLT) during cycle 1.
    date_rangeTime Frame:
    Up to 1 year
    enhanced_encryption
    Safety Issue:
    Yes

Secondary Outcome

  • Maximum total drug concentration (Cmax)
    date_rangeTime Frame:
    Cycle 1, Day 1 and Day 15 (each cycle is 28 days)
    enhanced_encryption
    Safety Issue:
    No
  • Area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24)
    date_rangeTime Frame:
    Cycle 1, Day 1 and Day 15 (each cycle is 28 days)
  • Area under the plasma concentration-time curve from time zero to infinity (AUC)
    date_rangeTime Frame:
    Cycle 1, Day 1 and Day 15 (each cycle is 28 days)
  • Time of maximum observed concentration (tmax)
    date_rangeTime Frame:
    Cycle 1, Day 1 and Day 15 (each cycle is 28 days)
  • Tumor response based on RECIST 1.1 or Cheson 2007 criteria
    date_rangeTime Frame:
    Up to 100 weeks
  • Biomarker evaluation by determination of MYC protein expression and PCNA mRNA
    PCNA: proliferating cell nuclear Antigen mRNA: messenger ribonucleic acid
    date_rangeTime Frame:
    Cycle 1, Day 1, Day 8 and Day 15 (each cycle is 28 days)

Trial design

An open-label Phase I dose-escalation study to characterize the safety, tolerability, pharmacokinetics, and maximum tolerated dose of BAY1143572 given in a once-daily or an intermittent dosing schedule in subjects with advanced malignancies
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
Non-randomized
Blinding
Open Label
Assignment
Parallel Assignment
Trial Arms
2